Copyright
        ©2014 Baishideng Publishing Group Inc.
    
    
        World J Gastroenterol. Dec 7, 2014; 20(45): 17011-17019
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.17011
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.17011
            Table 1 MicroRNAs involved in angiogenesis
        
    | MicroRNAs | Target genes/activators | Effect on angeogenesis | Ref. | 
| miR-194 | THBS1 | ↑ Enhance | [69] | 
| miR-221, miR-222 | c-Kit, Stat5A, ENOS, and ETS1 | ↓ Inhibit | [70] | 
| miR-17-92 (Oncomir-1) | TSP-1 and CTGF | ↑ Enhance | [71] | 
| miR-126 | SPRED1 and PIK3R2 p85beta | ↑ Enhance | [72] | 
| miR-210 | Hypoxia-induced miR-210 activation accompanied by KRAS mutation | ↑ Enhance | [73] | 
| miR-497 | IGF1-R | ↓ Inhibit | [74] | 
| miR-424 | Hypoxia-induced activation of angiogenic genes | ↑ Enhance | [75] | 
            Table 2 MicroRNAs and invasion
        
    | MicroRNAs | Dysregulation | Remarks | Ref. | 
| miR-31 | ↑ | Contributed to the invasive nature of CRC cells in vitro and in vivo | [76] | 
| miR-122 | ↑ | Non-neoplastic tissue to dysplasia | [77] | 
| ↓ | Dysplasia to inflammatory bowel disease-associated CRC | [77] | |
| miR-200 family | ↑ | Associated with acquiring an aggressive phenotype | [78] | 
| miR-328 | ↓ | Accompanied by a high fraction of side population (SP) cells showing cancer stem like properties | [79] | 
| miR-143 | ↓ | Stimulated cell growth, migration and invasion | [80] | 
| miR-145, miR-103 and miR-107 | ↑ | Promoted local invasion and liver metastasis in a mouse model | [81] | 
| miR-29a | ↑ | Elevated in CRC tumor samples compared to normal epithelial tissue; a specific and sensitive marker discriminating CRC with liver metastases from non-metastatic CRC | [82,83] | 
| miR-21, miR-17, miR-19a | ↑ | Favored cell proliferation and CRC metastasis | [84] | 
            Table 3 Intravasation, extravasation and colonization
        
    | MicroRNAs | Dysregulation | Effect | Ref. | 
| Intravasation and extravasation | |||
| miR-21 | ↓Pdcd4 | ↑ Intravasation and metastatic potential | [34,85] | 
| miR-126 | ↓VCAM-1 | ↓ Decreased cell-cell adhesion, leukocytes-epithelial cell adherence, inflammation | [86] | 
| miR-155 | Required for adaptive and innate immunity | [40] | |
| miR-17-92 | Adaptive differentiation of B cells and conventional T cells | [40] | |
| Colonization | |||
| miR-328 | ↓ in SP cells | Low miR-328 expression correlated with high SP fraction | [79] | 
| miR-26b | ↓ HUES-17 and CRC cell line | ↓ Cell growth and induction of apoptosis | [87] | 
| miR-103/107 | ↓DAPK and KLF4 | ↑ Colonization | [69] | 
            Table 4 MicroRNAs as diagnostic markers
        
    | MicroRNAs | Sensitivity | Specificity | Remarks | Ref. | 
| Plasma | ||||
| miR-29a | 69% | 89.1% | Upregulated in CRC plasma, associated with advanced TNM stages | [82] | 
| miR-92a | 64% | 70% | Upregulated in CRC plasma; could distinguish CRC from other GI cancers and IBD; not associated with TNM stages | [50] | 
| miR-17-3p | 89% | 70% | Upregulated in CRC plasma | [51] | 
| miR-92a | 84% | 71.2% | Upregulated in CRC plasma; not associated with TNM stages | [82] | 
| Fecal | ||||
| miR-17-92 cluster | 69.5% | 81.5% | Upregulated in stool of CRC patients | [88] | 
| miR-135 | 46.2% | 95% | Upregulated in stool of CRC patients | [88] | 
| miR-92a | 50% | 80% | Upregulated in stool of CRC patients | [89] | 
| miR-21 | 50% | 83% | Upregulated in stool of CRC patients | [89] | 
            Table 5 MicroRNAs as therapeutic, potential prognostic and predictive markers for colorectal cancer
        
    | MicroRNAs | Dysregulation | Clinical phenotypes | Ref. | 
| miR-221 | Upregulated in CRC | Prognostic factors for poor overall survival in CRC patients | [90] | 
| miR-141 | Upregulated in CRC | Higher level associated with poor survival; an independent prognostic factor for advanced CRC | [71] | 
| pre-miR-423 | Upregulated in CRC | SNPs in these miRNAs were significantly associated with recurrence-free survival in CRC | [91] | 
| pre-miR-608 | Upregulated in CRC | [91] | |
| miR-222 | Upregulated in CRC | Played a role in the development of MDR by modulation of ADAM-17 in CRC | [79,92] | 
| miR-328 | Upregulated in CRC | Chemotherapeutic insensitive CRC cells, carrying stem cell-like properties, could be reversed by restoring miR-328 to normal | [79] | 
| let-7g | Upregulated in CRC | Higher level associated with poor S-1 response; was prognostic in early-stage CRC | [10,93] | 
| miR-18a | Upregulated in CRC | Higher level associated with poor overall survival | [94] | 
| miR-21 | Upregulated in adenoma, CRC, and liver metastases | Higher level associated with lymph node metastasis, poor survival, poor therapeutic outcomes, rapid recurrence, and shorter disease-free interval | [88] | 
| miR-31 | Upregulated in CRC | Higher level associated with higher TNM stages and local invasion | [91] | 
| miR-106a | Upregulated in colon cancer | Higher level associated with longer disease-free survival and overall survival | [10] | 
| miR-143 | Downregulated in colon cancer and liver metastases | Lower level associated with larger tumour size and longer disease-free interval; expression levels served as an independent prognostic biomarker for KRAS wild-type CRC | [65,91] | 
| miR-145 | Downregulated in CRC | Lower level associated with large tumour size and tumour location | [65,91] | 
| miR-181b | Upregulated in CRC | Higher level associated with poor S-1 response | [10] | 
| miR-320 | Downregulated in MSS tumour | Lower level associated with shorter progression-free survival | [94] | 
| miR-498 | Downregulated in MSS tumour | Lower level associated with shorter progression-free survival | [94] | 
- Citation: Muhammad S, Kaur K, Huang R, Zhang Q, Kaur P, Yazdani HO, Bilal MU, Zheng J, Zheng L, Wang XS. MicroRNAs in colorectal cancer: Role in metastasis and clinical perspectives. World J Gastroenterol 2014; 20(45): 17011-17019
- URL: https://www.wjgnet.com/1007-9327/full/v20/i45/17011.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i45.17011

 
         
                         
                 
                 
                 
                 
                 
                         
                         
                        